Abstract: The invention relates to methods for inhibiting S. suis comprising administering to CATH2 or a derivative thereof and to methods for the treatment or prevention of a S. suis infection in a subject in need thereof, comprising administering CATH2 or a derivative thereof to the subject.

Abstract: The invention relates to methods for activating, inducing or promoting innate immune memory in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof. The invention further relates to methods of improving antimicrobial treatment in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof and to a use of CATH2 or a derivative thereof as an adjuvant for a pathogen-specific vaccine.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.

Abstract: The invention relates to the field of antibiotics, more specifically to peptide antibiotics, such as antimicrobial peptides and their use in the treatment of diseases associated with microbial infections. In particular, the invention provides a peptide with antimicrobial activity comprising an amino acid sequence RRWVQRWIRRWR (SEQ ID NO: 24) or an analogue thereof.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The invention relates to the field of antibiotics, more specifically to peptide antibiotics, such as antimicrobial peptides and their use in the treatment of diseases associated with microbial infections. In particular, the invention provides a peptide with antimicrobial activity comprising an amino acid sequence RRWVQRWIRRWR (SEQ ID NO: 24) or an analogue thereof.

Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.

Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retro-inverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.

Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.

Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.

Abstract: An ultrasonic flow-measuring method determines the flow rate of a medium flowing through a line is determined by measuring the runtime of an ultrasonic signal that travels from a first ultrasonic transducer to at least one other ultrasonic transducer. The runtime of the ultrasonic signal as it makes m passes in immediate succession through a predefined path over a predefined path length and at a predefined angle relative to the flow direction is measured, and the runtime of the ultrasonic signal as it makes n passes in immediate succession through the predefined path over the predefined path length at the predefined angle relative to the flow direction is measured, with m and n being mutually different integers, and the dead time of the ultrasonic flow-measuring process is determined on the basis of the measured runtimes. This ultrasonic flow-measuring method permits real-time compensation for the dead time during the actual measuring process, the result being highly accurate measurements.

Abstract: An ultrasonic flow-measuring method determines the flow rate of a medium flowing through a line is determined by measuring the runtime of an ultrasonic signal that travels from a first ultrasonic transducer to at least one other ultrasonic transducer. The runtime of the ultrasonic signal as it makes m passes in immediate succession through a predefined path over a predefined path length and at a predefined angle relative to the flow direction is measured, and the runtime of the ultrasonic signal as it makes n passes in immediate succession through the predefined path over the predefined path length at the predefined angle relative to the flow direction is measured, with m and n being mutually different integers, and the dead time of the ultrasonic flow-measuring process is determined on the basis of the measured runtimes. This ultrasonic flow-measuring method permits real-time compensation for the dead time during the actual measuring process, the result being highly accurate measurements.